Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pierre Fenaux

Showing results (11-20 of 432) with videos related to

Pageof 44
Sort By:
Hematology. American Society of Hematology. Education Program|December 14, 2011
Immunomodulating drugs in myelodysplastic syndromesLionel Adès, Pierre Fenaux
Blood Reviews|February 2, 2010
Impact of iron overload in myelodysplastic syndromesPierre Fenaux, Christian Rose
Leukemia|July 15, 2020
Which lower risk myelodysplastic syndromes should be treated with allogeneic hematopoietic stem cell transplantation?Marie Robin, Pierre Fenaux
Seminars in Hematology|January 13, 2015
Treatment of myelodysplastic syndrome with thrombomimetic drugsValeria Santini, Pierre Fenaux
Bulletin Du Cancer|August 9, 2011
[Hypomethylating agents for the treatment of myelodysplastic syndromes]Raphael Itzykson, Pierre Fenaux
Current Opinion in Hematology|May 27, 2009
Optimal sequencing of treatments for patients with myelodysplastic syndromesRaphael Itzykson, Pierre Fenaux
British Journal of Haematology|April 16, 2008
Farnesyltransferase inhibitors and their potential role in therapy for myelodysplastic syndromes and acute myeloid leukaemiaThorsten Braun, Pierre Fenaux
Hematology. American Society of Hematology. Education Program|November 25, 2006
Treatment of the 5q- syndromePierre Fenaux, Charikleia Kelaidi
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 12, 2011
Hypomethylating agents and other novel strategies in myelodysplastic syndromesGuillermo Garcia-Manero, Pierre Fenaux
Pathologie-Biologie|June 28, 2002
[Prognostic factors in myelodysplasia syndromes]Pierre Fenaux, Stéphane de Botton
Pageof 44

Showing results (11-20 of 432) with videos related to

Sort By:
Pageof 44
Hematology. American Society of Hematology. Education Program|December 14, 2011
Immunomodulating drugs in myelodysplastic syndromesLionel Adès, Pierre Fenaux
Blood Reviews|February 2, 2010
Impact of iron overload in myelodysplastic syndromesPierre Fenaux, Christian Rose
Leukemia|July 15, 2020
Which lower risk myelodysplastic syndromes should be treated with allogeneic hematopoietic stem cell transplantation?Marie Robin, Pierre Fenaux
Seminars in Hematology|January 13, 2015
Treatment of myelodysplastic syndrome with thrombomimetic drugsValeria Santini, Pierre Fenaux
Bulletin Du Cancer|August 9, 2011
[Hypomethylating agents for the treatment of myelodysplastic syndromes]Raphael Itzykson, Pierre Fenaux
Current Opinion in Hematology|May 27, 2009
Optimal sequencing of treatments for patients with myelodysplastic syndromesRaphael Itzykson, Pierre Fenaux
British Journal of Haematology|April 16, 2008
Farnesyltransferase inhibitors and their potential role in therapy for myelodysplastic syndromes and acute myeloid leukaemiaThorsten Braun, Pierre Fenaux
Hematology. American Society of Hematology. Education Program|November 25, 2006
Treatment of the 5q- syndromePierre Fenaux, Charikleia Kelaidi
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 12, 2011
Hypomethylating agents and other novel strategies in myelodysplastic syndromesGuillermo Garcia-Manero, Pierre Fenaux
Pathologie-Biologie|June 28, 2002
[Prognostic factors in myelodysplasia syndromes]Pierre Fenaux, Stéphane de Botton
Pageof 44